Optimal Cost-Effectiveness Decisions: The Role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI)

Goeree, 2002, Cost-effectiveness and cost-utility of long-term management strategies for heartburn, Value Health, 5, 312, 10.1046/j.1524-4733.2002.54145.x

Miller, 2003, Counseling versus antidepressant therapy for the treatment of mild to moderate depression in primary care: economic analysis, Int J Technol Assess Health Care, 19, 80, 10.1017/S0266462303000084

Ramsey, 2003, Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema, N Engl J Med, 348, 2092, 10.1056/NEJMsa030448

Legood, 2006, Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies, BMJ, 332, 79, 10.1136/bmj.38698.458866.7C

Coast, 2004, Is economic evaluation in touch with society's health values?, BMJ, 329, 1233, 10.1136/bmj.329.7476.1233

Koerkamp, 2007, Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis, Med Decis Making, 27, 101, 10.1177/0272989X06297394

Kamath, 2003, The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis, Value Health, 6, 144, 10.1046/j.1524-4733.2003.00215.x

Elliott, 2006, Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?, Rheumatology (Oxford), 45, 606, 10.1093/rheumatology/kei241

Brown, 2006, A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review with economic modelling, Health Technol Assess, 10, 1, 10.3310/hta10380

Weinstein, 1990, Principles of cost-effective resource allocation in health care organizations, Int J Technol Assess Health Care, 6, 93, 10.1017/S0266462300008953

Cantor, 1994, Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment, Med Decis Making, 14, 259, 10.1177/0272989X9401400308

Claxton, 2002, A rational framework for decision making by the National Institute For Clinical Excellence (NICE), Lancet, 360, 711, 10.1016/S0140-6736(02)09832-X

Sculpher, 2005, Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty—when is there sufficient evidence?, Value Health, 8, 433, 10.1111/j.1524-4733.2005.00033.x

Fenwick, 2006, An iterative Bayesian approach to health technology assessment: application to a policy of pre-operative optimization for patients undergoing major elective surgery, Med Decis Making, 26, 480, 10.1177/0272989X06290493

Claxton, 1999, The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies, J Health Econ, 18, 341, 10.1016/S0167-6296(98)00039-3

O'Hagan, 2005, Incorporation of uncertainty in health economic modelling studies, Pharmacoeconomics, 23, 529, 10.2165/00019053-200523060-00001

Fenwick, 2001, Representing uncertainty: the role of cost-effectiveness acceptability curves, Health Econ, 10, 779, 10.1002/hec.635

UK BEAM Trial Team, 2004, United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care, BMJ, 329, 1381, 10.1136/bmj.38282.607859.AE

Black, 1990, The CE plane: a graphic representation of cost-effectiveness, Med Decis Making, 10, 212, 10.1177/0272989X9001000308

Briggs, 2006

van Hout, 1994, Costs, effects and C/E-ratios alongside a clinical trial, Health Econ, 3, 309, 10.1002/hec.4730030505

Fenwick, 2004, Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions, Health Econ, 13, 405, 10.1002/hec.903

Claxton, 1999, Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals, Health Econ, 8, 269, 10.1002/(SICI)1099-1050(199905)8:3<269::AID-HEC425>3.0.CO;2-D

Claxton, 2005, When is evidence sufficient?, Health Affairs, 24, 93, 10.1377/hlthaff.24.1.93

Ades, 2006, Bayesian methods for evidence synthesis in cost-effectiveness analysis, Pharmacoeconomics, 24, 1, 10.2165/00019053-200624010-00001

Briggs, 1999, A Bayesian approach to stochastic cost-effectiveness analysis, Health Econ, 8, 257, 10.1002/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO;2-E

Briggs, 2002, Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease, Med Decis Making, 22, 290, 10.1177/027298902400448867

Palmer, 2000, Incorporating option values into the economic evaluation of health care technologies, J Health Econ, 19, 755, 10.1016/S0167-6296(00)00048-5

Ades, 2003, Correlations between parameters in risk models: estimation and propagation of uncertainty by Markov Chain Monte Carlo, Risk Anal, 23, 1165, 10.1111/j.0272-4332.2003.00386.x

Chessa, 1999, Correlations in uncertainty analysis for medical decision making: an application to heart-valve replacement, Med Decis Making, 19, 276, 10.1177/0272989X9901900306